GlassScriptPhysician profile
Patrick J Sellers
NPI 1205342268
$3,170.86
in general payments reported to CMS, 2019-2025
32 companies · $209 in 2025
The $209 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $655 · 2022: $707 · 2023: $1,113 · 2024: $487 · 2025: $209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,789 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,788.68 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $503.19 | 2021-2025 | |
| Glaxosmithkline, LLC. | $498.82 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Otsuka America Pharmaceutical, INC. | $364.51 | 2022-2024 | Rexulti |
| Amgen INC. | $312.34 | 2021-2024 | Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $272.95 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $240.63 | 2021-2024 | Relistor, Xifaxan |
| Lilly USA, LLC | $148.68 | 2021-2024 | Mounjaro, Jardiance |
| Pfizer INC. | $80.71 | 2023-2025 | |
| Amarin Pharma, INC. | $76.36 | 2021-2022 | |
| Novo Nordisk INC | $60.81 | 2021-2025 | Ozempic |
| Astrazeneca Pharmaceuticals LP | $58.00 | 2021-2024 | Farxiga |
| Merck Sharp & Dohme LLC | $57.47 | 2022-2023 | Belsomra |
| Exact Sciences Corporation | $54.26 | 2023-2024 | Cologuard Collection Kit |
| Lundbeck LLC | $49.24 | 2023-2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $48.61 | 2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $45.01 | 2022 | |
| Acadia Pharmaceuticals INC | $36.18 | 2021-2023 | Nuplazid |
| Janssen Pharmaceuticals, INC | $23.74 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.04 | 2023 | Synjardy, Tradjenta, Jardiance |
| Xeris Pharmaceuticals, INC. | $20.35 | 2022 | |
| Neurocrine Biosciences, INC. | $19.21 | 2023 | Ingrezza |
| Jazz Pharmaceuticals INC. | $19.10 | 2021 | |
| Astellas Pharma US INC | $17.45 | 2024 | Veozah |
| Corium, LLC | $17.00 | 2023 | Azstarys |
| Harmony Biosciences LLC | $16.81 | 2024 | |
| Idorsia Pharmaceuticals US INC | $16.80 | 2022 | |
| Axsome Therapeutics, INC. | $16.50 | 2024 | Auvelity |
| Novartis Pharmaceuticals Corporation | $16.36 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $15.42 | 2023 | Austedo Xr |
| Biohaven Pharmaceuticals, INC. | $14.64 | 2021 | |
| Medtronic, INC. | $14.49 | 2023 | Minimed 770g |
| Sumitomo Pharma America, INC. | $14.18 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Sellers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.